Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
for Non-Small Cell Lung Cancer
28 locations incl. Irvine
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 18+
Code: NCT07100080·Phase 2, Phase 3·Recruiting